CBER/CDER Cultures Are Similar, Galson Says; Will Familiarity Breed Content?
Executive Summary
"Cultural differences" will not be a significant obstacle in the consolidation of FDA's drug and biologic reviews, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, maintained during the Food & Drug Law Institute Annual Educational Conference in Washington, D.C., April 2
You may also be interested in...
CBER/CDER Transition Begins In June: Application Assignments “99.99%” Set
The reorganization of the Center for Biologics Evaluation & Research and Center for Drug Evaluation & Research is scheduled to take effect on June 30 with the detailing of approximately 200 employees from CBER to CDER
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
The CBER/CDER reorganization working group is finalizing a list of approved and investigational products whose reviews would be shifted from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011